Cancer Research Meeting Calendar Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kumar-Sinha, C.
Right arrow Articles by Chinnaiyan, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kumar-Sinha, C.
Right arrow Articles by Chinnaiyan, A. M.
[Cancer Research 63, 132-139, January 2003]
© 2003 American Association for Cancer Research

Molecular Biology and Genetics

Transcriptome Analysis of HER2 Reveals a Molecular Connection to Fatty Acid Synthesis1

Chandan Kumar-Sinha, Kathleen Woods Ignatoski, Marc E. Lippman, Stephen P. Ethier and Arul M. Chinnaiyan2

Departments of Pathology [C. K-S., A. M. C.], Radiation Oncology [K. W. I., S. P. E.], Internal Medicine [M. E. L.], and Urology [A. M. C.] and the Comprehensive Cancer Center [M. E. L., S. P. E., A. M. C.], University of Michigan Medical School, Ann Arbor, Michigan 48109

HER2 (erbB2/neu) is a member of the erbB family of receptor tyrosine kinases and is involved in regulating the growth of several types of human carcinomas. HER2 represents a successful therapeutic target of the biotechnology era as exemplified by the drug Herceptin (trastuzumab), which has clinical activity in a subset of breast cancer patients. Using DNA microarrays, we identified a cohort of genes that are differentially regulated by HER2 in breast epithelial cells. One of the HER2-regulated genes discovered was fatty acid synthase (FAS), which has been shown to be overexpressed in breast cancer as well as other cancers. FAS is implicated in tumorigenesis through its role in cell proliferation and membrane lipid incorporation of neoplastic cells. Here, we demonstrate that HER2-mediated induction of FAS is inhibitable by Herceptin and tyrosine kinase inhibitors of HER2. Through a phosphatidylinositol 3'-kinase-dependent pathway, HER2 stimulates the FAS promoter and ultimately mediates increased fatty acid synthesis. Interestingly, pharmacological inhibition of FAS preferentially induced apoptosis of HER2-overexpressing breast epithelial cells relative to matched vector control cells. These studies characterize a molecular connection between two genes individually implicated in tumorigenesis but never linked together.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
J. Ross, A. M. Najjar, M. Sankaranarayanapillai, W. P. Tong, K. Kaluarachchi, and S. M. Ronen
Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine
Mol. Cancer Ther., August 1, 2008; 7(8): 2556 - 2565.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Vincent-Salomon, C. Lucchesi, N. Gruel, V. Raynal, G. Pierron, R. Goudefroye, F. Reyal, F. Radvanyi, R. Salmon, J.-P. Thiery, et al.
Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast
Clin. Cancer Res., April 1, 2008; 14(7): 1956 - 1965.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Furuta, S. K. Pai, R. Zhan, S. Bandyopadhyay, M. Watabe, Y.-Y. Mo, S. Hirota, S. Hosobe, T. Tsukada, K. Miura, et al.
Fatty Acid Synthase Gene Is Up-regulated by Hypoxia via Activation of Akt and Sterol Regulatory Element Binding Protein-1
Cancer Res., February 15, 2008; 68(4): 1003 - 1011.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
J. Ursini-Siegel, A. B. Rajput, H. Lu, V. Sanguin-Gendreau, D. Zuo, V. Papavasiliou, C. Lavoie, J. Turpin, K. Cianflone, D. G. Huntsman, et al.
Elevated Expression of DecR1 Impairs ErbB2/Neu-Induced Mammary Tumor Development
Mol. Cell. Biol., September 15, 2007; 27(18): 6361 - 6371.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Yoon, M.-Y. Lee, S. W. Park, J.-S. Moon, Y.-K. Koh, Y.-H. Ahn, B.-W. Park, and K.-S. Kim
Up-regulation of Acetyl-CoA Carboxylase {alpha} and Fatty Acid Synthase by Human Epidermal Growth Factor Receptor 2 at the Translational Level in Breast Cancer Cells
J. Biol. Chem., September 7, 2007; 282(36): 26122 - 26131.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Zhou, W. F. Han, L. E. Landree, J. N. Thupari, M. L. Pinn, T. Bililign, E. K. Kim, A. Vadlamudi, S. M. Medghalchi, R. El Meskini, et al.
Fatty Acid Synthase Inhibition Activates AMP-Activated Protein Kinase in SKOV3 Human Ovarian Cancer Cells
Cancer Res., April 1, 2007; 67(7): 2964 - 2971.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
W. B. Kinlaw, J. L. Quinn, W. A. Wells, C. Roser-Jones, and J. T. Moncur
Spot 14: A Marker of Aggressive Breast Cancer and a Potential Therapeutic Target
Endocrinology, September 1, 2006; 147(9): 4048 - 4055.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. Lupu and J. A. Menendez
Targeting Fatty Acid Synthase in Breast and Endometrial Cancer: An Alternative to Selective Estrogen Receptor Modulators?
Endocrinology, September 1, 2006; 147(9): 4056 - 4066.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. P. Kuhajda
Fatty Acid synthase and cancer: new application of an old pathway.
Cancer Res., June 15, 2006; 66(12): 5977 - 5980.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
X. Liu, Y. Shi, V. L. Giranda, and Y. Luo
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis.
Mol. Cancer Ther., March 1, 2006; 5(3): 494 - 501.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
D. Zhang, L. K. Tai, L. L. Wong, L.-L. Chiu, S. K. Sethi, and E. S. C. Koay
Proteomic Study Reveals That Proteins Involved in Metabolic and Detoxification Pathways Are Highly Expressed in HER-2/neu-positive Breast Cancer
Mol. Cell. Proteomics, November 1, 2005; 4(11): 1686 - 1696.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. A. Menendez, L. Vellon, and R. Lupu
Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene
Ann. Onc., August 1, 2005; 16(8): 1253 - 1267.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
A. Astolfi, L. Landuzzi, G. Nicoletti, C. De Giovanni, S. Croci, A. Palladini, S. Ferrini, M. Iezzi, P. Musiani, F. Cavallo, et al.
Gene Expression Analysis of Immune-Mediated Arrest of Tumorigenesis in a Transgenic Mouse Model of HER-2/neu-Positive Basal-Like Mammary Carcinoma
Am. J. Pathol., April 1, 2005; 166(4): 1205 - 1216.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. Lu and M. C. Archer
Fatty acid synthase is a potential molecular target for the chemoprevention of breast cancer
Carcinogenesis, January 1, 2005; 26(1): 153 - 157.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
O. M. Sinilnikova, S. M. Ginolhac, C. Magnard, M. Leone, O. Anczukow, D. Hughes, K. Moreau, D. Thompson, C. Coutanson, J. Hall, et al.
Acetyl-CoA carboxylase {alpha} gene and breast cancer susceptibility
Carcinogenesis, December 1, 2004; 25(12): 2417 - 2424.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. A. Menendez, L. Vellon, I. Mehmi, B. P. Oza, S. Ropero, R. Colomer, and R. Lupu
Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells
PNAS, July 20, 2004; 101(29): 10715 - 10720.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. J. Kridel, F. Axelrod, N. Rozenkrantz, and J. W. Smith
Orlistat Is a Novel Inhibitor of Fatty Acid Synthase with Antitumor Activity
Cancer Res., March 15, 2004; 64(6): 2070 - 2075.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Zhou, P. J. Simpson, J. M. McFadden, C. A. Townsend, S. M. Medghalchi, A. Vadlamudi, M. L. Pinn, G. V. Ronnett, and F. P. Kuhajda
Fatty Acid Synthase Inhibition Triggers Apoptosis during S Phase in Human Cancer Cells
Cancer Res., November 1, 2003; 63(21): 7330 - 7337.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
S. Rossi, E. Graner, P. Febbo, L. Weinstein, N. Bhattacharya, T. Onody, G. Bubley, S. Balk, and M. Loda
Fatty Acid Synthase Expression Defines Distinct Molecular Signatures in Prostate Cancer
Mol. Cancer Res., August 1, 2003; 1(10): 707 - 715.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.